Skip to main content
main-content

Oncology

Latest articles

17-12-2018 | Rheumatology | News | Article

Lupus tied to increased cancer risk

Findings from a meta-analysis indicate that systemic lupus erythematosus is associated with an increased risk for 16 types of cancer.

14-12-2018 | Small-cell lung cancer | News | Article

Veliparib shows efficacy in some patients with extensive-stage SCLC

Some patients with extensive-stage small-cell lung cancer may benefit from the addition of the poly(ADP ribose) polymerase inhibitor veliparib to standard chemotherapy, but further confirmation of its efficacy is needed, say researchers.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.18.00264

13-12-2018 | Breast cancer | News | Article

Trastuzumab emtansine targets residual invasive HER2-positive breast cancer

Adjuvant trastuzumab emtansine halves the risk of invasive disease recurrence or death versus trastuzumab in patients with residual invasive human epidermal growth factor receptor 2-positive early breast cancer, researchers report.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1814017
SABCS 2018; San Antonio, Texas, USA; 4–8 December

11-12-2018 | Oncology | Highlight | Article

Editor's pick

Direct oral anticoagulants AVERT VTE events in patients with cancer

The results of the randomized CASSINI and AVERT trials support the prophylactic use of the direct oral anticoagulants rivaroxaban and apixaban in cancer patients undergoing chemotherapy who are at risk for venous thromboembolism events.

Source:

ASH 2018; San Diego, California, USA; 1–4 December
N Engl J Med 2018; doi:10.1056/NEJMoa1814468

10-12-2018 | Lymphoma | News | Article

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7
ASH 2018; San Diego, California, USA; 1–4 December

07-12-2018 | Breast cancer | Video

PD-L1 in immune cells predicts atezolizumab plus nab-paclitaxel efficacy in metastatic triple-negative breast cancer

Presenting author Leisha Emens outlines exploratory efficacy analysis results from IMpassion130 showing that programmed cell death ligand 1 in immune cells is a robust predictive biomarker for selecting women with metastatic triple-negative breast cancer who may benefit from first-line atezolizumab plus nab-paclitaxel treatment (6:19).

image credits